<DOC>
	<DOCNO>NCT00334295</DOCNO>
	<brief_summary>The purpose study determine efficacy monthly administration Fulvestrant patient recurrent metastatic endometrial carcinoma assessment clinical tumour response 3 injection .</brief_summary>
	<brief_title>Fulvestrant Treatment Recurrent Metastatic Endometrial Carcinoma .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Histologically confirm , recurrent metastatic endometrial carcinoma Postmenopausal Hormonreceptor positive Pretreatment Fulvestrant Previous endocrine therapy endometrial carcinoma Previous malignancy le 3 year ago situ carcinoma cervix , basal cell carcinoma squamous carcinoma skin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Recurrent metastatic endometrial carcinoma</keyword>
</DOC>